Tagged with IP

China PharmaBoardroom caught up with Dr Jingsong Wang, chairman & CEO of Harbour BioMed to discuss the exciting clinical and commercial milestones of the prolific biotech in the last year since we last met them in January 2019, including their March USD 75 million Series B+ fundraising round and their preparations…

Mexico Mauricio Guizar, newly appointed general manager of Ipsen Mexico since October 2019, shares his first impression of the French specialty care player’s operations in Mexico, the significance of being the first Mexican GM in the local market, as well as his focus on positioning Ipsen as a partner to the…

Romania Amalia Mihai, market access manager of Ipsen Romania explains that over the course of 26 years Ipsen has been increasingly helping Romanian patients in the field of oncology, neurodegenerative disorders, gastroenterology and endocrinology. She reveals that a successful market launch entails having a patient-centric approach, supporting patients not only with…

Romania Jorge Levinson, head of Bayer Pharmaceuticals Romania and Moldova, reveals his first impressions of Romania and the untapped potential it offers to the company. He shares his insights on how close-knit partnerships with the government, patient and medical associations are key and discloses his ambition to create an organisational culture…

India A recent IQVIA report highlights the increasing importance of Indian firms to the USA’s burgeoning generic pharmaceuticals market.   Now accounting for over 90 percent of all prescriptions dispensed in the USA, generic drugs play a vital role within US healthcare and have come a long way since their use…

Czech Republic Pharma industry stakeholders are generally quick to suggest that the Czech Republic is one of the most over-regulated markets in Europe, with new or innovative therapies facing significant delays before being able to enter the market.   While the timelines are still outside the defined framework, the situation is much…

Morocco Layla Sentissi, executive director of AMIP, Morocco’s oldest pharma association, explains the structure of the country’s pharmaceutical industry and its key developments, lays down her ambition to create a National Pact for Medicines, discusses the key challenges for the local industry, and invites global decision-makers of to the Africa Health…

Czech Republic Patrik Zachar, Vice President Central Europe of Ipsen, shares how the company has built a strong presence in oncology and neuroscience in the CE region and the Czech Republic, quickly establishing market-leading positions in the indications they compete in. Whilst in neuroscience, Zachar still sees significant growth potential for its…

Hungary Hungary’s longstanding tradition of pharmacology is a major point of pride for the country’s scientists and researchers who today have hopes to elevate the country’s research environment to a region-leading position once more through new models of industry-academia collaboration.   Strength in CNS Hungary has a very strong tradition in…

Hungary According to Peter Holchacker, director general of Hungary’s Association of Innovative Pharmaceutical Manufacturers (AIPM), “clinical trials initiated by multinational companies, represent, on average, an investment of approximately EUR 300 million each year.” Furthermore, Dr György Bodoky, founder and honorary president of the Hungarian Society of Clinical Oncology (MKOT), adds that…

USA In 2019, several drug companies testified to the US Senate Finance Committee on medicine price hikes with a narrative of discounts given to health insurance companies and pharmacists, but not then passed onto consumers. In a recent conversation with PharmaBoardroom, Matt Eyles, president & CEO of the Association of Healthcare…

UAE From Turkey to Tajikistan, Bangladesh to Bahrain, and Russia to Rwanda, multinational pharma firms are increasingly situating wide-ranging management responsibilities in the UAE. The following is an inexhaustive list of some of the widely varying geographies being managed from the UAE, as well as insights from the executives overseeing them.…